# A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors

Source: https://onco.cc/trials/nct04686682/  
OnCo record `nct04686682` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of JAB-8263 in non-small-cell lung cancer, small-cell lung cancer and ovarian cancer, run by Jacobio Pharmaceuticals Co., Ltd., now recruiting.

## Summary

A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors is a phase 1/2 interventional study registered as NCT04686682 by Jacobio Pharmaceuticals Co., Ltd., with 152 participants planned, started 2021-05-07 and due to reach its primary completion in 2028-01. Interventions recorded: JAB-8263.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04686682
- Phase: 1/2
- Setting: A Phase I/IIa, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-8263 in Adult Patients With Advanced Malignant Tumors
- Sponsor: Jacobio Pharmaceuticals Co., Ltd.
- Enrolled: 152

## Sources

- ClinicalTrials.gov NCT04686682: https://clinicaltrials.gov/study/NCT04686682

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- companies: [Jacobio Pharmaceuticals](https://onco.cc/companies/jacobio-pharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/nct04686682.json